Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: REZULIN

« Back to Dashboard
Rezulin is a drug marketed by Pfizer Pharms and is included in one NDA. There are four patents protecting this drug.

The generic ingredient in REZULIN is troglitazone. Additional details are available on the troglitazone profile page.

Summary for Tradename: REZULIN


Clinical Trials for: REZULIN

Troglitazone in Treating Patients With Liposarcoma
Status: Active, not recruiting Condition: Sarcoma

TART - Troglitazone Atherosclerosis Regression Trial
Status: Completed Condition: Atherosclerosis; Diabetes Mellitus

Fracture Risk With Thiazolidinediones
Status: Completed Condition: Fractures, Bone; Type II Diabetes

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
Status: Completed Condition: Type 2 Diabetes Mellitus; Impaired Glucose Tolerance

Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diabetes Mellitus
Status: Completed Condition: Diabetes Mellitus, Type 2

Association Study of Genetic Polymorphisms of Candidate Genes With Thiazolidinedione-Related Peripheral Edema and Drug Responsiveness
Status: Recruiting Condition: Diabetes Mellitus

Lumbar Spinal Fusion System
Status: Completed Condition: Degenerative Disc Disease

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Pharms
TABLET;ORAL020720Aug 4, 1997DISCNNo6,046,202<disabled><disabled>
Pfizer Pharms
TABLET;ORAL020720Jan 29, 1997DISCNNo5,602,133<disabled><disabled>
Pfizer Pharms
TABLET;ORAL020720Jan 29, 1997DISCNNo6,046,202<disabled><disabled>
Pfizer Pharms
TABLET;ORAL020720Aug 4, 1997DISCNNo5,859,037<disabled><disabled>
Pfizer Pharms
TABLET;ORAL020720Jan 29, 1997DISCNNo5,859,037<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: REZULIN

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
February 11, 2009
January 12, 2011
January 04, 2012
April 04, 2008
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn